PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting

Shots:Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonistRichard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumabThe interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumorsSmriti: Explain the details (MOA, ROA, formulations, etc.)…